- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05332002
진행성 위식도암에서의 sFOLFOXIRI, (SAGE)
진행성 위식도암(SAGE)에서 sFOLFOXIRI의 제2상 연구
The primary objective is to determine the clinical efficacy of treatment regimen in terms of objective response rate (ORR). The secondary objectives is to determine the clinical efficacy of the study treatment in terms of progression free survival (PFS) and overall survival (OS). Additionally, to characterize the safety and toxicity profile of the study treatment as measured by the adverse event rates.
연구 개요
상세 설명
The overall purpose of this protocol is to serve as a Single Arm Phase II trial of a four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI), with or without nivolumab, in advanced human epidermal growth factor receptor two (HER2) negative gastric and esophageal cancers (GEC). This study evaluates the hypothesis that the use of sFOLFOXIRI in gastroesophageal cancer (GEC) will increase response rates beyond that expected with FOLFOX, while maintaining acceptable tolerability. The primary endpoint of this study is the objective response rate (ORR) while the key secondary endpoints include the progression free survival (PFS), overall survival (OS), and adverse event (AE) rates. The goal of this study is to establish the activity level of sFOLFOXIRI, with the thought that this could be further developed in the metastatic and/or peri-operative space if a sufficiently interesting degree of efficacy is observed.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Patrick Boland, MD
- 전화번호: (732)235-2465
- 이메일: pb564@cinj.rutgers.edu
연구 장소
-
-
New Jersey
-
Hamilton, New Jersey, 미국, 08690
- 모병
- RWJBarnabas Health - Robert Wood Johnson University Hospital
-
연락하다:
- Patrick Boland, MD
-
Lakewood, New Jersey, 미국, 08701
- 모병
- RWJBarnabas Health - Monmouth Medical Center Southern Campus
-
연락하다:
- Patrick Boland, MD
-
Long Branch, New Jersey, 미국, 07740
- 모병
- RWJBarnabas Health - Monmouth Medical Center
-
연락하다:
- Patrick Boland, MD
-
New Brunswick, New Jersey, 미국, 08903
- 모병
- Rutgers Cancer Institute of New Jersey
-
연락하다:
- Patrick Boland, MD
-
New Brunswick, New Jersey, 미국, 08903
- 모병
- RWJBarnabas Health - Robert Wood Johnson University Hospital, Somerset
-
연락하다:
- Patrick Boland, MD
-
Newark, New Jersey, 미국, 07112
- 모병
- RWJBarnabas Health - Newark Beth Israel Medical Center
-
연락하다:
- Patrick Boland, MD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Histologically and/or cytologically confirmed metastatic or unresectable adenocarcinoma of esophageal, gastroesophageal junction or gastric origin
-
Tumor is HER2 negative by standard local testing methodology
-
Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 - 2
-
Measurable disease by response evaluation criteria in solid tumors (RECIST) v1.1
-
No prior systemic therapy for the present cancer given in the metastatic setting and > 6 months from administration of peri-operative chemotherapy, if applicable
o Note: up to two prior cycles of mFOLFOX6 for the present illness is permitted if patients otherwise qualify for the study with adequate baseline imaging
-
At least 18 years of age
-
Adequate bone marrow and organ functions as defined by:
-
Absolute neutrophil count ≥ 1500 cells/ μL
-
Hemoglobin ≥ 8 g/ dL
-
Platelets > 100,000 / μL
-
Creatinine ≤ 1.5 x upper limit of normal (ULN) OR creatinine clearance ≥ 30 mL/min by Cockroft-Gault
-
Total bilirubin ≤ ULN
-
Aspartate aminotransferase (AST)/ Alanine aminotransferase (ALT) < 2.5 x ULN, unless with liver metastases and then must be <5 x ULN of normal
-
Women and men of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect pregnancy on study, she must notify her treating physician immediately.
-
Ability to understand the nature of this study protocol and give written informed consent.
-
Willingness and ability to comply with scheduled visits, treatment plans laboratory tests and other study procedures.
Exclusion Criteria:
- Receipt of any investigational agents at the time of registration
- Known, untreated brain metastases
- Grade two or greater peripheral neuropathy
- Presence of any additional active malignancy within the past three years where the malignancy is at least reasonably likely to later the course of therapy, require systemic therapy or interfere with imaging assessments
- For those patients who are going to receive nivolumab
- No active use of systemic corticosteroids at the time of enrollment, at a dose equivalent of 10 mg/day or prednisone
- Clinically significant autoimmune disease which is active or has required systemic immunosuppression within the last two years
- Prior organ transplant or bone marrow transplant
- History of interstitial lung disease or pneumonitis
- Uncontrolled intercurrent illness, including significant active infection, symptomatic congestive heart failure, unstable angina or active arrhythmia
- Major surgery within the four weeks prior to initiation of study treatment
- A history of allergy or hypersensitivity to any of the study drugs
- Any additional significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from fully participating in the study
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
다른: 4week alternating FOLFOX and a combination chemotherapy regime FOLFIRI (sFOLFOXIRI),
A cycle will constitute 28 days of treatment, which will consist of one chemotherapy combination, either FOLFOX or FOLFIRI as below:
|
This is a Single Arm Phase II trial of q4week alternating FOLFOX and FOLFIRI (sFOLFOXIRI), with or without nivolumab, in advanced human epidermal growth factor receptor 2 (HER2) negative gastric and esophageal cancers (GEC). The study treatment is a chemotherapy combination of either FOLFOX or FOLFIRI as below:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
부작용 비율
기간: 삼 년
|
삼 년
|
|
|
Objective Response Rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors ( RECIST) criteria version 1.1
기간: Three Years
|
To determine the clinical efficacy of treatment regimen in terms of objective response rate. |
Three Years
|
|
Progression Free Survival (PFS)
기간: Three Years
|
To determine the clinical efficacy of the study treatment in terms of progressive free survival. |
Three Years
|
|
Overall Survival (OS)
기간: Three Years
|
To determine the clinical efficacy of the study treatment in terms of overall survival. |
Three Years
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Patrick Boland, MD, Rutgers Cancer Institute of New Jersey
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
- 072204
- Pro2022000268 (기타 식별자: Rutgers Cancer Institute of New Jersey)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .